Zevra Therapeutics (ZVRA) FCF Margin (2019 - 2026)
Zevra Therapeutics' (ZVRA) quarterly FCF Margin came in at 16.86% in Q1 2026, up 5765.0% YoY from 0.29% in Q1 2025, and up 3.86% on a QoQ basis from 16.23% in Q4 2025.
Zevra Therapeutics (ZVRA) FCF Margin (2019 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 8 years of FCF Margin data on file, last reported at 16.86% in Q1 2026.
- Quarterly FCF Margin rose 5765.0% year-over-year to 16.86% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9.81% (up 16242.0% YoY) and the FY2025 annual result came in at 2.29%, up 29276.0% from the prior year.
- FCF Margin climbed to 16.86% in Q1 2026, from 16.23% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 16.86% in Q1 2026 to a low of 1167.81% in Q2 2022.
- A 5-year average of 229.32% and a median of 131.78% in 2024 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin sank 130618 bps — and 2023, when it surged 106478 bps.
- Tracing ZVRA's FCF Margin over 5 years: stood at 198.66% in 2022, then soared by 37 bps to 125.62% in 2023, then fell by 8 bps to 135.28% in 2024, then soared by 112 bps to 16.23% in 2025, then increased by 4 bps to 16.86% in 2026.
- The last three FCF Margin figures came in at 16.86% (Q1 2026), 16.23% (Q4 2025), and 15.94% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | 42.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.36% |
| Mar 31, 2026 | 16.86% |
| Dec 31, 2025 | 16.23% |
| Sep 30, 2025 | 15.94% |
| Jun 30, 2025 | -14.74% |
| Mar 31, 2025 | -40.79% |
| Dec 31, 2024 | -135.28% |
| Sep 30, 2024 | -490.96% |
| Jun 30, 2024 | -434.30% |
| Mar 31, 2024 | -471.97% |
| Dec 31, 2023 | -125.62% |
| Sep 30, 2023 | -165.80% |
| Jun 30, 2023 | -103.03% |
| Mar 31, 2023 | -128.27% |
| Dec 31, 2022 | -198.66% |
| Sep 30, 2022 | -240.86% |
| Jun 30, 2022 | -1,167.81% |
| Dec 31, 2021 | -33.50% |
| Sep 30, 2021 | -142.14% |
| Jun 30, 2021 | 138.37% |